English to Russian Medical Medical: Pharmaceuticals

BAT1806 has a good treatment effect on IL-6 related diseases such as adult rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, giant lymph node hyperplasia and cytokine storm caused by immunotherapy.
In the antibody formulations provided by the invention, in order to keep the stability of the humanized anti-interleukin 6 receptor antibody, an appropriate buffer system was selected, a stabilizer was optimized and a surfactant was added, and through a large amount of research work, antibody formulations have been developed to remarkably inhibit the formation of acidic peaks, dimers, aggregates, degradants and insoluble microparticles during freezing/thawing cycles, long-term storage and *temperature variation processes*.

In particular, the humanized anti-interleukin 6 receptor antibodies remain stable in the above formulations after at least 5 freeze-thaw cycles, stable at room temperature for at least 6 months, and stable at 4 °C for 36 months.
Therefore, the antibody formulations of the present invention can be used for stably storing the humanized anti-interleukin 6 receptor antibody for clinical treatment, which has a great significance for treating relevant diseases caused by IL-6.